NEW YORK – Immunocore kwuru na Mọnde na ọ ga-ere òkè 3,733,333 na nkwekọrịta ego itinye ego nkeonwe (PIPE) nke a na-atụ anya na ọ ga-enweta nde dọla 140.
N'okpuru nkwekọrịta ahụ, Immunocore ga-ere ngwaahịa nkịtị ya na nke na-abụghị nke ntuli aka maka $37.50 kwa òkè. Ndị na-etinye ego na ụlọ ọrụ ahụ dị ugbu a na-etinye aka na ego ahụ gụnyere RTW Investments, Rock Springs Capital na General Atlantic. A na-atụ anya na nkwekọrịta PIPE ga-akwụsị na Julaị 20.
Ụlọ ọrụ a ga-eji ego a na-enweta kwado ndị na-achọ ọgwụgwọ ọrịa kansa na ọrịa na-efe efe, gụnyere mmepe nke onye na-azọ ọkwa n'ọkwa kansa, Kimmtrak (tebentafusp-tebn), iji gwọọ akpụkpọ ahụ dị mma HLA-A*02:01 na melanoma uveal. A na-atụ anya na ego a, yana ego sitere na Kimmtrak, ga-akwado ọrụ Immunocore ruo 2025.
Afọ a, a kwadoro Kimmtrak ka o jiri ya mee ihe n'ime ndị nwere HLA-A*02:01 positive unresectable ma ọ bụ metastatic uveal melanoma na US, Europe na UK, tinyere mba ndị ọzọ. Immunocore na-aga n'ihu na-amụ ọgwụ ahụ na ọmụmụ Phase I/II na HLA-A*02:01-positive cudenageal melanoma.
Immunocore na-emepụtakwa ọgwụ ndị ọzọ anọ a na-akpọ oncology, gụnyere ọgwụ T-cell receptor abụọ ọzọ na nnwale Phase I/II na etuto siri ike dị elu. A na-emepụta otu n'ime ọgwụ ndị a maka ndị nwere HLA-A*02:01-positive na MAGE-A4-positive, nke ọzọ na-elekwasị anya na etuto HLA-A*02:01 na PRAME-positive. Ụlọ ọrụ ahụ nwekwara ndị nwere ọrịa kansa abụọ a na-akọwaghị nke ọma na mmepe tupu ọgwụgwọ.
Amụma Nzuzo. Usoro na Ọnọdụ. Ikike Nwebiisinka © 2022 GenomeWeb, ngalaba azụmaahịa nke Crain Communications. ikike niile echekwabara.